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Abstract
Background: The development of mucosal vaccines is crucial to efficiently control infectious agents for which mucosae are
the primary site of entry. Major drawbacks of these protective strategies are the lack of effective mucosal adjuvant. Synthetic
oligodeoxynucleotides that contain several unmethylated cytosine-guanine dinucleotide (CpG-ODN) motifs are now
recognized as promising adjuvants displaying mucosal adjuvant activity through direct activation of TLR9-expressing cells.
However, little is known about the efficacy of these molecules in stimulating the intestinal immune system in neonates.
Methodology/Principal Findings: First, newborn mice received CpG-ODN orally, and the intestinal cytokine and chemokine
response was measured. We observed that oral administration of CpG-ODN induces CXC and CC chemokine responses and
a cellular infiltration in the intestine of neonates as detected by immunohistochemistry. We next compared the efficiency of
the oral route to intraperitoneal administration in stimulating the intestinal immune responses of both adults and neonates.
Neonates were more responsive to TLR9-stimulation than adults whatever the CpG-ODN administration route. Their
intestinal epithelial cells (IECs) indirectly responded to TLR9 stimulation and contributed to the CXC chemokine response,
whereas other TLR9-bearing cells of the lamina-propria produced CC chemokines and Th1-type cytokines. Moreover, we
showed that the intestine of adult exhibited a significantly higher level of IL10 at homeostasis than neonates, which might
be responsible for the unresponsiveness to TLR9-stimulation, as confirmed by our findings in IL10-deficient mice.
Conclusions/Significance: This is the first report that deciphers the role played by CpG-ODN in the intestine of neonates.
This work clearly demonstrates that an intraperitoneal administration of CpG-ODN is more efficient in neonates than in
adults to stimulate an intestinal chemokine response due to their lower IL-10 intestinal level. In addition we report the
efficiency of the oral route at inducing intestinal chemokine responses in neonate that might be taken into consideration for
further vaccine development against neonatal diseases.
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Introduction
Neonates and infants have an increased susceptibility to infection
due to inherent limitations of their immune system. It is believed
that neonates exhibit functionally impaired antigen presentation,
shorter lived and weaker antibody responses, a Th2-type immune
response bias and a decreased overall cell-mediated immune
response if compared with adults [1]. However, under appropriate
conditions, neonates can develop immune responses to vaccination
that are qualitatively and quantitatively similar to adults [2–5].
Themucosal surfacesare the primary site ofentry of most pathogens
and thus the development of vaccines delivered mucosally should help
to promote mucosal immune responses, as well as providing a safe,
readily acceptable method for inducing systemic immune responses.
One of the major drawbacks in the development of mucosal vaccines
has been the lack of effective mucosal adjuvants [6].
Bacterial DNA has direct immunostimulatory effects due to the
presence of unmethylated cytosine–guanine dinucleotides (CpG)
within a particular base context (CpG motifs) [7]. Synthetic
oligodeoxynucleotides (ODN) that contain one or more CpG
motifs and mimic bacterial DNA are now recognized as promising
adjuvants. CpG-ODN has strong adjuvant activity due to its many
effects on both innate and adaptive immune responses. Indeed,
CpG ODN can directly activate monocytes, macrophages and
dendritic cells to secrete IFN-a/b, IL-6, IL-12, GM-CSF,
chemokines, and TNF-a, which in turn stimulate T-cells and
natural killer (NK) cells to produce additional cytokines, such as
IFN-c. CpG-ODN also causes up-regulation of co-stimulatory
molecules and MHC class II molecules, improving antigen
presentation by professional cells. In response to CpG-ODN
stimulation, B-cells proliferate, secrete immunoglobulins and
provide a T-helper function by strong Type 1-like patterns of
cytokine production that is dominated by IL-12 and IFN-a, with
little secretion of Type 2 cytokines [8,9].
The use of CpG-ODN as a potent Th1-like adjuvant for
mucosal vaccinations with various antigens has been largely
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Moreover, many preclinical and early clinical trials indicate that
synthetic CpG-ODN has potent immunostimulatory effects and
can enhance the activity of various anti-cancer treatments [11].
These immunostimulatory properties of CpG-ODN can also be
efficiently used without antigens to control infectious diseases such
as listeriosis [12] and Helicobacter pylori infection [13]. We have
previously reported that CpG-ODN administered orally to
newborn mice confers 90% protection against Cryptosporidium
parvum enteric infection [14]. However, despite increasing
knowledge about the immunostimulatory effects of CpG-ODN
systemically administered in adult mice, there is still limited
information on the efficiency of such molecules on the intestinal
innate immune system when delivered to newborns.
We therefore studied the mucosal immune response following
an oral administration of CpG-ODN to neonates, and investigated
the contribution of intestinal epithelial cells (IECs) and the
neonatal environment in this response.
Materials and Methods
Reagents
Rat anti-neutrophil clone 7/4, rat anti-B220 clone RA3-6B2,
rat anti CD8a clone YTS105.18 and hamster anti-CD11c clone
HL3 were purchased from Serotec, rat anti-CD4 clone
YTS191.1.2 from Cedarlane and were used for immunofluores-
cence analysis. The expression of cell surface molecules by flow
cytometry was analyzed using the following antibodies purchased
from BD pharmingen: anti-CD11c antibodies conjugated with
FITC or PE (HL3), anti-CD8a-PE (53-6.7), anti-CD4 (H129.19),
and anti-CD19 (ID3) antibodies.
CpG-ODN 1668 (for murine cells) was purchased from Sigma-
Aldrich.
Mice and In Vivo Treatment
C57BL/6J female mice with or without litters were housed
under specific pathogen-free conditions, and were maintained at
constant temperature and humidity, with food and water given ad
libitum. C57BL/6 IL10-deficient mice were kindly provided by
Richard Lo-Man (Institut Pasteur, France) and C57BL/6 TLR9-
deficient mice by Shizuo Akira (Osaka University, Japan). Eight-
day-old neonates and 6-8-week-old adult mice received CpG-
ODN by oral (20 mg/g) and by intraperitoneal (10 mg/g) route.
Experimental protocols were designed in compliance with
recommendations of the French law (De ´cret: 2001-464 29/05/01)
and EEC (86/609/CEE) for the care and use of laboratory animals.
Purification of Intestinal Epithelial Cells (IEC)
Purification of IEC was performed as described previously by
Perreault and Beaulieu with some modifications [15]. The small
intestine was opened longitudinally, washed in phosphate-buffered
saline (PBS) and cut into 5-mm fragments. The fragments
obtained were transferred into a flask with ice-cold Matrisperse
(BD biosciences), and incubated at 4uC for 8–10 h without
agitation. The flask was then gently shaken to separate the
epithelium. The mixture was passed through 100 mm and then
60 mm filters and epithelium was recovered on the 60 mm filter.
After washes, epithelial cells were individually separated by
trypsination. Cells were then stained with phycoerythrin-labeled
anti-CD4, CD8, CD11b, and NK1.1 antibodies. Cells were sorted
by MoFlo (Dako) according to SSC-FSC and PE non-positivity.
The viability of purified IEC after sorting was about 85%. Two
hours after in vitro cultivation, viability of IEC was about 60%.
For neonates, ten intestines were pooled to obtain one value.
Immunohistology
Pieces of ileum from neonatal mice were frozen at 280uCi n
embedding matrix for immunohistological studies. Frozen sections
(7 mm) were cut and fixed in acetone gradient and incubated with
primary antibodies for 2 h at room temperature. Sections were
washed several times in PBS, and were then incubated with an
anti-rat AlexaFluor 594 conjugate (Molecular Probes) and an anti-
hamster biotin conjugate (Jackson ImmunoResearch), for 1 h at
room temperature. Sections were finally washed and incubated
with ExtrAvidine fluorescein isothiocyanate conjugate (Sigma) for
20 minutes. Sections were counterstained with Hoechst nuclear
dye and observed on a Zeiss fluorescence microscope with the
Axiovision software (Zeiss, Go ¨ttingen, Germany).
Collection of Mesenteric Lymph Node Cells and FACS
Mesenteric lymph nodes (MLN) were removed from neonates
and placed in Petri dishes with cold RPMI 1640 medium
(Invitrogen). They were crushed on 60 mm Blutex and cells were
spun for 5 min at 1,500 rpm at 4uC. Cells were resuspended in PBS
supplementedwith 1%FCS.Weused 10
6 cellsforeachstainingand
non-specific staining was prevented by first blocking the cells with
anti-CD16/CD32 antibody (2.4G2; BD Pharmingen). Cells were
incubated with the antibodies for 30 minutes, fixed in 2%
paraformaldehyde and sorted on a Becton-Dickinson fluores-
cence-activated cell sorter (FACS) with the CellQuest-Pro software.
mICcl2 and CMT93 Cultures
The murine cell line mICcl2 was kindly provided by A.
Vandewalle [16]. This immortalized cell line is from the crypt of
the small intestine of mice and was maintained at 37uC in the
presence of 5% CO2 on growth medium containing Dulbecco
modified Eagle medium and Ham’s F12 medium at a ratio of 1:1
(vol/vol), 60 nM sodium selenate, 5 mg of transferrin per ml,
2 mM glutamine, 5 mg of insulin per ml, 50 nM dexamethasone,
5 nM triiodothyronine, 10 ng of epidermal growth factor per ml,
20 mM D-glucose, 2% fetal calf serum, and 20 mM HEPES
(pH 7.4). Murine rectal adenocarcinoma (CMT-93) cell lines were
grown in DMEM supplemented with 10% heat-inactivated fetal
calf serum, 4 mM glutamine, 100 U of penicillin per ml, 100 mgo f
streptomycin per ml, and 1% nonessential amino acids in a 5%
CO2 incubator at 37uC. Cells were seeded into 6-well plastic tissue
culture plates and were stimulated when they reached confluence.
RNA Extraction and Reverse-Transcription (RT) Reaction
Ilea were removed from adult and neonate mice. Ilea were
placed in TRIzol (InVitrogen) and were crushed with an Ultra-
Turrax homogenizer. The samples were centrifuged at 8,0006g to
eliminate debris, and the supernatants were stored at 280uC until
further processing. RNA was extracted according to the
manufacturer’s instructions and quantified by measuring absor-
bance at 260 nm. RNA quality was estimated by agarose gel
electrophoresis, using ethidium bromide staining.
Analysis of Inflammatory Cytokines, Chemokines and
Their Receptor mRNA Levels by Reverse Transcription
(RT)-PCR Array
Gene expression for inflammatory cytokines, chemokines and their
receptors was measured using the real-time PCR-based pathway-
focused gene profiling ‘‘RT2 profiler system’’ from SuperArray, Inc.
(mouse inflammatory cytokines and receptor PCR Array). Procedures
were carried out according to the manufacturer’s protocol. Briefly,
1 mg of total RNA was used as template for the reverse transcription of
cDNA. The cDNA was diluted and added to a master mix containing
Effect of CpG on Neonates
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a 96-well plate: each well contained previously dispensed gene-specific
primer sets. The plates were then placed in the Chromo4 (Bio-Rad),
and real-time PCR analysis was performed. Each plate contained a
panel of housekeeping gene primers for normalizing PCR array data,
and estimating the linear dynamic range of the assay. Furthermore,
‘‘no reverse transcription’’ and ‘‘no template’’ samples were included as
negative controls for each reaction. Raw data were acquired and
processed with the Chromo4 (Bio-Rad) to calculate the threshold cycle
(Ct) value and relative gene expression values, subsequently determined
according to the standard DDCt method.
Analyses of Gene mRNA Levels by RT-PCR
Total RNA (2 mg) was reverse transcribed using oligo(dT)
primers and Moloney murine leukemia virus reverse transcriptase,
according to the manufacturer’s instructions (Eurogentec), in a
total volume of 20 ml. Synthesized cDNA (2 ml) diluted 1/100 was
then amplified by PCR in the Chromo4 (Bio-rad). Hypoxanthine
phosphoribosyltransferase mRNA levels were used to normalize
RNA quantification. We used various primers for mRNA
quantification: the previously described HPRT, IFNc, IL12,
CCL2 and CCL7 primers [14,17], TLR9 (forward:
CCGCCCAGTTTGTCAGAGG; reverse: GGGGTACAGA-
CTTCAGGAACAG), CXCL10 (forward: CACGTGTTGAGA-
TCATTGCCA; reverse: GCGTGGCTTCACTCCAGTTA),
CXCL1 (forward: CGCTCGCTTCTC TGTGCAGC; reverse:
GTGGCTATGACTTCGGTTTGG), FoxP3 (forward: ATCTC-
CTGGATGAGAAAGGCAAGG; reverse: TGTTGTGGAA-
GAACTCTGGGAAGG), and IL10 (forward: GGTTGC-
CAAGCCTTATCGGA; reverse: CTGCTCCACTGCCTTGC-
TCTTATT).
Statistics
Non-parametric analyses were performed with the Mann-
Whitney tests.
Results
Th1-Type Cytokine Response after CpG-ODN Treatment
CpG-ODN is known to be a strong Th1 inducer; thus, the
capacity of orally administered CpG-ODN to increase IL12p40
and IFNc mRNA levels in the intestine of 8-day old newborn mice
was evaluated by real-time RT-PCR. CpG-ODN given orally
significantly increased IFNc and IL12p40 mRNA levels in
comparison with sham-treated litters: mRNA levels were 23-
and 37-fold greater, respectively, 6 h after administration (Fig. 1A
and B). These data are in agreement with our previous results
obtained with 1–2 day-old orally-treated neonates [14]. This
response was strictly TLR9-dependent, as this overexpression was
absent in the mucosa of TLR9-deficient newborns treated with
oral CpG-ODN (Fig. 1A and B).
Recruitment of Inflammatory Cells into the Intestinal
Mucosa and Draining Lymph Nodes of Neonates after
Oral Administration of CpG-ODN
The intestinal mucosa in newborns is significantly less colonized
by immune cells than that in adults. We characterized the capacity
of orally given CpG-ODN to induce immune cell recruitment in
the intestinal mucosa of neonates. Eight-day-old mice received a
single oral dose of 20 mg/g of CpG-ODN, and 24 h later a
significant recruitment of CD11c+ dendritic cells, B220+ B cells,
CD4+ and CD8+ cells and neutrophils was observed in the
intestinal mucosa (Fig. 2). Thus, CpG-ODN administered orally
induced a rapid recruitment of a broad range of immune cells to
the newborn intestinal mucosa. To investigate whether orally
given CpG-ODN also triggered cell trafficking into the draining
lymph nodes, mesenteric lymph nodes (MLN) were removed from
neonates 24 h after treatment with CpG-ODN and the cell
composition phenotype was determined by flow cytometry. We
observed greater numbers of CD4+ (x3), CD8+ (x5.5), CD19+ (x3)
and CD11c+ (x8) cells in neonates after a single dose of CpG-
ODN given orally than in those treated with PBS (Fig. 3).
Chemokine and Cytokine Responses in Mice after
Treatment with CpG
To better characterize the inflammatory response induced in
neonates by CpG-ODN treatment, chemokines, small proteins
principally involved in inflammation regulation and leukocyte
trafficking, were measured by an RT-PCR array. This assay allows
the simultaneous analysis of mRNA levels for 84 genes encoding
inflammatory cytokines, chemokines and their receptors. Immune
responses in the ileum of neonates were analyzed 6 h after oral
CpG-ODN treatment. A very high overexpression of three CXC-
nonELR chemokines (CXCL9, 10, 11) was observed (680-, 989-,
and 436-fold increases, respectively) (Fig. 4A). CXCL9, 10 and 11
exert their functional effects through interactions with a specific
high-affinity G-protein–coupled receptor, CXCR3, which is
Figure 1. IL12p40 and IFNc responses after CpG-ODN treatment in the intestine. CpG-ODN was administered orally in 8-day-old WT and
TLR9 KO neonate mice at a dose of 20 mg/g (black boxes). Control mice received PBS orally (white boxes). N=5 neonates from two different litter for
each group. Six hours later, ilea were removed for RNA extraction. RT-PCRs were performed for amplification of IL12p40 (A) and IFNc (B) mRNA. These
data are representative of two experiments. Data were analyzed by the non-parametric Mann-Whitney test.
doi:10.1371/journal.pone.0008291.g001
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phenotype, and which has been detected in T-cells isolated from a
diverse number of inflammatory tissues [18]. mRNA levels of
CXCL5 and CXCL1, known to recruit neutrophils, were also
increased (380- and 28-fold greater, respectively). Other ELR+-
CXC chemokine mRNA levels, such as those for CXCL4, 12, 13
and 15, did not vary after CpG-ODN treatment. Among the CC
chemokines analyzed, increases of CCL2 (157-fold), CCL4 and
CCL7 (73- and 76-fold, respectively), CCL3 and CCL5 (36- and
53-fold, respectively) and to a lesser extent those of CCL11,
CCL12, CCL17 and CCL22 (6- to 11-fold increases) were
observed. Several interleukins were also been analyzed with this
method, and the pro-inflammatory cytokine IL1b (8-fold greater),
the regulatory cytokine IL10 (52-fold greater) and IL15 (7-fold
greater) were up-regulated after CpG-ODN treatment. TNFa
mRNA levels were also moderately greater than in individuals
without treatment (14-fold) (Fig. 4A). Finally, our analysis of
cytokine or chemokine receptor mRNA production did not reveal
any significant change, suggesting that 6 h of stimulation was not
sufficient to either upregulate receptor mRNA levels in the few
immune cells present in the mucosa, or more probably was
insufficient at inducing a significant recruitment of immune cells
bearing receptors in the mucosa (data not shown).
Comparison of Mucosal Chemokine Responses between
Adult and Neonatal Mice after Oral or Intraperitoneal
Administration of CpG-ODN
We selected two CC and two CXC chemokines for which over
expression in the mucosa of neonates treated orally with CpG-
ODN was high: CCL2, CCL7, CXCL1 and CXCL10 were
chosen to compare the efficiency of orally administered CpG-
ODN to stimulate intestinal immune responses in neonates and in
adult mice. A real-time RT-PCR analysis revealed that the
amounts of CCL2 and CCL7 mRNA were greater in neonates
after oral CpG administration (154-fold and 44-fold greater,
respectively) than in adults (Fig. 4B). We also observed higher
CXCL10 and CXCL1 mRNA levels in neonatal intestinal mucosa
(neonates: 975-fold and 26-fold greater, respectively; adult: 15-fold
and 3-fold greater, respectively). We then wondered if this effect
was specific to the oral route. After IP administration, an increased
expression of CXCL10 (57-fold), CXCL1 (16-fold) and CCL7 (5-
fold) in the mucosa of adult mice was observed, but these
upregulations were weaker than those observed in neonates (700-,
23-, 75- and 62-fold greater for CXCL10, CXCL1, CCL2 and
CCL7 respectively). Taken together, these results showed that
neonates responded more efficiently to CpG-ODN than adult
Figure 2. Recruitment of inflammatory cells in the intestine of neonates after CpG-ODN treatment. Eight-day-old neonatal mice received
20 mg/g of CpG-ODN orally. Twenty-four hours after treatment, ilea were removed to analyze the recruitment of inflammatory cells by
immunohistology. Six to ten neonates from different litters (5 sections for each animal) per group were analyzed. Data were analyzed by non-
parametric Mann-Whitney test.
doi:10.1371/journal.pone.0008291.g002
Figure 3. Recruitment of inflammatory cells in the MLN after
CpG-ODN treatment. Eight-day-old neonatal mice received 20 mg/g
of CpG-ODN by the oral route. Twenty-four hours later, MLN from 10
neonates were removed and pooled for FACS analysis. Four pools in
each group were analyzed. These data were from two representative
experiments. Mann-Whitney non parametric test ** p,0.005, * p,0.05.
doi:10.1371/journal.pone.0008291.g003
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PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8291mice, and that administering CpG-ODN orally is particularly
efficient in neonates.
Response of Freshly Purified Intestinal Epithelial Cells
(IEC) to In Vitro Stimulation with CpG-ODN
Intestinal epithelial cells are the first cells associated with the
digestive tract that might respond to oral adjuvant stimulation. We
compared mRNA levels of the CpG-ODN receptor, TLR9, in
IECs freshly purified from adult and neonates, to study how
neonate intestinal epithelial cells (IEC) contribute to the
stimulation of efficient innate immune responses triggered by
CpG-ODN. IECs from adults had about 10 times more mRNA
than neonates (Fig. 5A). When freshly purified IECs were
stimulated in vitro with CpG-ODN, neonatal IECs did not respond
to stimulation; CXCL10 mRNA levels in adults were about 5-fold-
greater than without CpG-ODN (Fig. 5B). This low overexpres-
sion was consistant with that observed within mouse IEC lines
ICcl2 and CMT93 stimulated with CpG-ODN (Fig. 5B).
Responses of Purified IECs from Adults and Neonates
after In Vivo Administration of CpG-ODN
Both the cellular environment and polarization of IECs may
influence responses to CpG-ODN. Therefore, in vivo CpG-ODN
stimulation was compared for drug administration by the oral and
IP route. IECs purified from neonates that received CpG-ODN by
oral or IP route displayed greater amounts of CXCL10 mRNA
(1720- and 1144-fold greater, respectively) and CXCL1 mRNA
(61- and 35-fold-greater, respectively), whereas those from adults
that received CpG-ODN by the IP route did not (Fig. 5C). No
expression of CCL2 and CCL7 chemokines has been detected in
freshly purified IEC preparations from adult and wild-type
neonates (data not shown). This suggests that IECs are key
contributors to CXCL1 and CXCL10 responses, but not to CCL2
and CCL7 responses measured in the mucosa of neonates.
Role of IL10 in Cytokine and Chemokine Responses after
CpG-ODN Administration
IL10 is a regulatory cytokine produced by DCreg, Treg or Breg
cells. In the intestine of adult mice, constitutive IL10 impairs
dendritic cell TLR stimulation from lamina propria [19].
Constitutive IL10 expression was higher (7-fold-higher) in the
intestine of adult mice than in neonatal intestines (Fig. 6A). Foxp3
expression is a hallmark of T regulatory cells that might produce
IL-10. In the intestine of adults the number of Foxp3+T cells was
not increased as suggested by the similar level of Foxp3 mRNA
expression within adults and neonates (Fig. 6A). We next
wondered if this difference in the constitutive IL10 mRNA level
between adults and neonates could explain the difference in
chemokine responses after CpG administration. To address this
question, IL10KO adult and neonatal mice received CpG-ODN
Figure 4. Mucosal immune responses after CpG-ODN treatment in the intestine. CpG-ODN was administered by the oral route in 8-day-old
neonates (n=5 for each group). Six hours later, ilea were removed for RNA extraction. (A) We used an RT-PCR microarray to analyze a pool of RNA for
each group. CC, CXC chemokines and cytokines/receptor data for values with greater than 3-fold-increases are represented. (B) Neonates (n=5) and
adults (n=5) received 20 mg/g CpG-ODN orally and 10 mg/g intraperitoneally. The mice were killed 6 hours later and the ilea were removed. RNAs
were extracted and RT-PCR analyses were performed for CCL2, CCL7, CXCL1 and CXCL10 expression. These data are representative of two
independent experiments. Data were submitted to the non-parametric Mann-Whitney test (*, p,0.05).
doi:10.1371/journal.pone.0008291.g004
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measured. As for wild-type mice, the administration of CpG-ODN
by oral route to IL10KO mice is much more efficient in neonates
than in adult to stimulate an intestinal chemokine response
(Fig. 6B). In contrast, in the absence of IL10, CpG-ODN
administration by IP route in adult mice induced an over-
expression of CXCL1 (400-fold greater), CXL10 (356-fold
greater), CCL2 (357-fold greater) and CCL7 (205-fold greater)
(Fig. 6B). These chemokine over-expressions were about 10- to 20-
fold higher and even about 300-fold for CCL2 than those observed
in adult IL10-sufficient mice (Fig. 6B). These results clearly
demonstrate than IL10 can negatively control CpG-ODN-induced
chemokine responses. It also suggests that higher levels of IL10 at
homeostasis in the adult intestine may contribute to the lower
chemokine responses after CpG treatment than observed in
neonatal mice.
Discussion
Neonates are highly sensitive to intestinal and respiratory
infection due to immune system immaturity [20]. Functional and
quantitative deficiencies, involving both non-specific innate
defenses and specific cellular and humoral defenses, have already
been described in newborns [2]. However, little is known about
neonatal gut mucosal immunology. The intestinal compartment in
neonates is almost devoid of immune cells and this could
contribute to the high sensitivity observed in response to intestinal
pathogens [17,21,22]. It is therefore of a particular interest to
develop strategies for the recruitment of immune cells in neonates
and for stimulating their intestinal immune system to improve
their resistance to infection. In this study, CpG-ODN, a potent
adjuvant and immunostimulant, was used to investigate its effect
on the intestinal immune response of neonates. Neonates displayed
an increased intestinal chemokine response after an oral
administration of CpG-ODN, which was associated with a large
recruitment of inflammatory cells. Surprisingly, this chemokine
response was much stronger than in adults. We therefore tried to
gain further insight into mechanisms in the intestinal immune
system of neonates responsible for this higher chemokine
responsiveness to orally administered CpG-ODN.
The immune effects of CpG-ODN are well described when
given by parenteral route, but little is known of its effects when
given orally. Neonatal mice receiving an oral dose of CpG-ODN
exhibited an increased intestinal response in chemokines belonging
to both CC and CXC chemokine families. The strong CXCL5
response and the CCL2, 3, 4 and 5 responses may have induced,
respectively, the recruitment of neutrophils and dendritic cells
observed 24 h after CpG-ODN administration. The upregulation
of the three nonELR-CXC chemokines CXCL9, 10 and 11 can be
linked to the significant recruitment of T cells. A production of
chemokines such as CCL2, 4, 5 and CXCL10 after an oral
administration of CpG was previously observed in the intestine of
adult mice [13,23]. Chemokine responses in the intestine of
neonates receiving CpG-ODN orally were much stronger than
those in adults. As IECs express TLR9 on their basal and apical
side [24], and are the first cells in contact with orally administered
CpG, these cells might contribute to these differences between
neonates and adults. Although basolateral TLR9 signals IkBa
degradation and activation of the NF-kB pathway, apical TLR9
stimulation invokes a unique response in which ubiquitinated IkB
accumulates in the cytoplasm preventing NF-kB activation [24].
This polarized response to CpG-ODN may explain the higher
chemokine response that we observed in the intestinal mucosa of
neonates compared with the response seen in adults. Closure of the
intestinal epithelium in neonates occurs after about 3 weeks [25],
and CpG-ODN given orally may have access to the basolateral
side of neonatal IECs, activating the NF-kB pathway and
producing chemokines such as CXCL1 and CXCL10. However,
direct in vitro stimulation of freshly purified IECs with CpG-
ODN, thus providing access to both sides of IECs, presented
CXCL10 mRNA levels in adults that were only slightly greater
than without CpG-ODN; moreover, no changes were observed in
neonatal IECs. This overexpression of CXCL10 was however
significantly weaker than that observed in neonatal IECs purified
after in vivo stimulation, suggesting that intestinal epithelial cells
are poorly responsive to direct CpG-ODN stimulation whatever
the age of the animal. There is increased evidence showing that
IECs are generally tolerogenic to direct TLR stimulation, avoiding
uncontrolled inflammation that is detrimental to the host. Several
mechanisms relating to TLR stimulation in IECs have been
previously described, such as the induction of negative regulators
Figure 5. Chemokine responses of intestinal epithelial cells
after CpG-ODN stimulation. (A) Intestinal epithelial cells (IEC) were
purified from neonatal (n=5) or adult mice (n=5). RNA was extracted
from the purified cells for TLR9 mRNA RT-PCR analysis. (B) Two murine
intestinal epithelial cell lines (ICcl2 and CMT93) and purified IECs from
adults and neonates were stimulated in vitro with 5 mg/ml of CpG-ODN
for 2 hours, and RNAs were extracted for CXCL1 and CXCL10
measurement. (C) Neonatal (n=30 for each group) and adult mice
(n=3 for each group) received CpG-ODN by the oral and IP route. They
were killed 6 hours later, and the IECs were purified. RNAs were
extracted and RT-PCR analyses were performed for CXCL1 and CXCL10
expression. Data were submitted to the non-parametric Mann-Whitney
test. (*, p,0.05). ND, Not Done.
doi:10.1371/journal.pone.0008291.g005
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there are few studies on the responses of neonatal IECs to TLR
stimulation. Similar to our findings with CpG-ODN, Lotz et al.
found that TLR4 stimulation with LPS increases KC and MIP2
chemokine production by IECs in fetuses and neonates, but that
this response was absent in adults. [22]. Our results suggest that
IECs are also tolerogenic to TLR9 stimulation, as early as the first
week after birth; This may occur to facilitate microbial
colonization in neonates and an intestinal host–microbe homeo-
stasis in adults.
IECs are poorly responsive to direct in vitro TLR9 stimulation.
However, our data with IECs purified after in vivo stimulation
with CpG show that they are major contributors to the CXCL1
and CXCL10 chemokine response measured in the intestinal
mucosa of neonates, and most probably play a role in the
neutrophil recruitment observed. Thus, our findings suggest that
other cells of the lamina propria produce CCL chemokines. These
cells probably contribute to the production of soluble factors that
can indirectly stimulate IECs for CXC chemokine production.
Differences in permeability between the intestinal epithelium of
adult and neonatal mice could explain why, in adults, the immune
cells of the lamina propria were less accessible to orally
administered CpG-ODN, leading to a weaker intestinal chemo-
kine response both in wild-type and IL10 KO mice. However, this
cannot explain why wild-type adult mice presented weaker CCL2,
CCL7 and CXCL10 intestinal responses after intraperitoneal
administration of CpG-ODN than neonatal mice. Indeed, we
could have expected a stronger response to CpG-ODN given by
the IP route in adult mice, due to the larger number of immune
cells bearing TLR9 in the lamina propria, than in neonates. These
results suggest that adult immune cells in the lamina propria are
less responsive to CpG-ODN than neonatal ones. These results are
consistent with other results on neonatal immune cells. By using a
model of kid neonates, we recently reported that neonatal cells
from mesenteric lymph nodes display a stronger TH1-type
cytokine response to TLR ligands than adults [27]. As intestinal
flora may affect TLR-ligand responsiveness, we performed an
experiment with germ free neonate and adult mice. Similar levels
of chemokine expression were observed following IP administra-
tion of CpG-ODN demonstrating that the intestinal flora as no
role in the difference of response observed between neonates and
adults (data not shown). We then addressed whether neonatal
Figure 6. Role of IL10 in the chemokine response induced by CpG-ODN stimulation. (A) Ilea of 8-day old neonatal (n=8) and of adult
(n=6) mice were removed for RNA extraction. IL10 and FoxP3 mRNA levels were measured by real-time RT-PCR. Data were analyzed by the non-
parametric Mann-Whitney test. (B) Neonates (n=3) and adults (n=3) IL10-deficient mice received PBS or 20 mg/g CpG-ODN orally and 10 mg/g
intraperitoneally. They were killed 6 hours later and the ilea were removed. Total RNAs were extracted and RT-PCR analyses were performed for
CXCL1, CXCL10, CCL2 and CCL7.
doi:10.1371/journal.pone.0008291.g006
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Despite FoxP3 mRNA expression, the hallmark of regulatory T
cells with similar expression levels in the mucosa of adults and
neonates, we observed IL10 mRNA levels in adult mouse mucosae
that were seven-fold greater than in neonates. This suggests that
this regulatory cytokine, produced by either B or dendritic cells,
could contribute to the reduced response to TLR9 stimulation in
adult mice. Adult IL10-deficient mice intraperitoneally stimulated
with CpG-ODN exhibited a stronger chemokine response than
wild-type adult mice, and display similar chemokine levels as
IL10KO neonatal mice that received CpG-ODN intraperitone-
ally. Therefore IL-10 intestinal levels affect chemokine respon-
siveness to TLR9 stimulation. Moreover, as wild-type neonates
express low levels of IL-10 in their intestine, the chemokine over-
expressions observed in IL-10 KO neonatal mice after CpG-ODN
administration were similar to the ones of wild-type mice.
Monteleone et al. have recently shown that dendritic cells from
adult mouse lamina propria are less responsive to TLR
stimulations due to a high constitutive production of IL10. This
is despite higher levels of TLR2, 3, 4 and 9 proteins than those
found in spleen and MLN DCs [19]. In the sheep model, Peyer’s
patch cells spontaneously secrete high levels of IL-10 and exhibit
poor cytokine responses (IFN-a, IFN-c and IL-12) following
stimulation with CpG-ODN compared with peripheral blood
mononuclear cells and lymph node cells [28]. Our findings are in
accordance with these observations, and clearly show that IL10 is
involved in the negative control of the intestinal immune response
to TLR9-stimulation in adult mice.
To summarize, CpG-ODN administered by oral route is very
efficient in neonates to induce a CCL and CXC chemokine
response and the recruitment of a panel of inflammatory cells in
the intestine. IECs respond indirectly to CpG-ODN and are major
contributors in the CXC chemokine response, whereas CC
chemokines seem to be produced by other cells of the lamina
propria, cells that are probably also the source of Th1-type
cytokines. Taken together, our findings suggest that the efficacy of
the oral route in neonates compared with adults is due to two
additional factors: the higher permeability of the intestinal barrier
before the closure of the epithelium, and an intestinal environment
with lower levels of IL10. Inducing this local immune response
could provide a great opportunity for controlling intestinal
intracellular pathogens in neonates, as we have previously
reported for cryptosporidiosis [14].
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